{"slug":"api-healthtravel-api-workers-dev-api-health-fda-purple-book-b6b733","title":"FDA Purple Book licensed biological products matching a name (brand or proper na","host":"api.healthtravel-api.workers.dev","method":"GET","resource":"https://api.healthtravel-api.workers.dev/api/health/fda-purple-book","category":"commerce","description":"FDA Purple Book licensed biological products matching a name (brand or proper name, e.g. adalimumab): applicant, BLA number, license type (351(a) originator, 351(k) biosimilar or interchangeable), strength, dosage form, route, marketing status, approval date, reference product and exclusivity expiry","price_listed":0.002,"price_asked":0.002,"state":"answering","state_label":"Answering","checks_7d":1,"answered_7d":1,"latency_ms_median":33,"reported_calls_30d":2,"reported_payers_30d":2,"networks":["eip155:10","eip155:137","eip155:143","eip155:42161","eip155:42220","eip155:480","eip155:5042","eip155:8453","solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","xrpl:0"],"badge":"unverified","paid_checks_7d":0,"paid_ok_7d":0,"example_input":{"method":"GET","queryParams":{"limit":"5","name":"adalimumab"},"type":"http"},"output_schema":{"$schema":"https://json-schema.org/draft/2020-12/schema","properties":{"input":{"additionalProperties":false,"properties":{"method":{"enum":["GET"],"type":"string"},"queryParams":{"properties":{"limit":{"description":"Products to return, 1 to 100 (default 25)","type":"string"},"name":{"description":"Brand or proper (nonproprietary) name, or BLA number (required)","type":"string"}},"required":["name"],"type":"object"},"type":{"const":"http","type":"string"}},"required":["type","method"],"type":"object"},"output":{"properties":{"example":{"type":"object"},"type":{"type":"string"}},"required":["type"],"type":"object"}},"required":["input"],"type":"object"},"history":[{"day":"2026-10-24","reachable":true,"status":402,"valid_402":true,"asked_usdc":0.002,"price_match":true,"latency_ms":33,"error":null}],"description_full":"FDA Purple Book licensed biological products matching a name (brand or proper name, e.g. adalimumab): applicant, BLA number, license type (351(a) originator, 351(k) biosimilar or interchangeable), strength, dosage form, route, marketing status, approval date, reference product and exclusivity expiry dates, plus the products newly approved or updated this month. From FDA's monthly Purple Book data download.","last_updated":"2026-10-23T20:25:55.804Z","schemes":["exact"]}